A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS ...

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier ...

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its ...

DelveInsight’s, “Glioma Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline ...

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

SAN FRANCISCO and SUZHOU, China, March 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated ...

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

With the newly completed OT-101 and IL-2 Phase 1 trial, Oncotelic is poised to begin further combination trials to determine the added efficacy of OT-101, IL-2, and CKIs in solid tumors such as lung ...

Through this partnership, NeOnc will initiate clinical trials across 30 FDA-compliant clinical research sites in India, increasing patient enrollment and accelerating development efforts for a novel ...